TrialPloS one2012

VS411 reduced immune activation and HIV-1 RNA levels in 28 days: randomized proof-of-concept study for antiviral-hyperactivation limiting therapeutics.

Franco Lori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.